BACKGROUND
Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new anti-tuberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.
METHODS
In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of M. tuberculosis. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months.
RESULTS
Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo (P=0.008). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P=0.04). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid.
CONCLUSIONS
Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.)
[1]Makati Med Ctr, Manila, Philippines.
[2]Trop Dis Fdn, Makati, Philippines.
[3]State Agcy TB & Lung Dis, Riga, Latvia.
[4]Hosp Nacl Sergio E Bernales, Lima, Peru.
[5]Hosp Nacl Daniel A Carrion, Unidad Invest, Lima, Peru.
[6]Hosp Nacl Hipolito Unanue, Lima, Peru.
[7]Shanghai Pulm Hosp, Shanghai, Peoples R China.
[8]Beijing Chest Hosp, Beijing, Peoples R China.
[9]Sadr Abassia Hosp, Cairo, Egypt.
[10]Natl Masan Hosp, Masan, South Korea.
[11]Asan Med Ctr, Seoul, South Korea.
[12]Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[13]Yonsei Univ, Med Ctr, Severance Hosp, Seoul 120749, South Korea.
[14]Univ Tartu, Lung Hosp, EE-50090 Tartu, Estonia.
[15]N Estonian Med Ctr Fdn, Ctr Pulmonol, Tallinn, Estonia.
[16]Fukujuji Hosp, Tokyo, Japan.
[17]Natl Hosp Org Kinki Chuo Chest Med Ctr, Osaka, Japan.
[18]Univ Texas Hlth Ctr Tyler, Tyler, TX USA.
[19]Otsuka Pharmaceut Dev & Commercializat, Rockville, MD USA.
(8.0+极速模式)